A meta-analysis of 10 RCTs with 6,257 participants found tirzepatide produced an average 11.62 kg weight loss versus placebo, with 88% achieving over 5% weight reduction at the highest dose and significant cardiometabolic improvements.
88.1% achieved >5% weight lossAt the 15 mg dose, nearly 9 out of 10 participants lost a clinically meaningful amount of weight, with over half losing more than 15% of body weight
What the researchers found
Across 10 RCTs with 6,257 participants, tirzepatide produced a pooled mean weight reduction of -11.62 kg compared to placebo (95% CI: -14.24 to -9.01, p < 0.001).
At the highest dose of 15 mg, weight loss milestones were impressive: 88.1% achieved >5% weight loss, 63.3% achieved >10%, and 51.8% achieved >15%. Significant improvements were observed across cardiometabolic markers including HbA1c, waist circumference, BMI, and lipid profiles. The safety profile was favorable with no increase in serious adverse events or mortality.
Why it matters
This comprehensive meta-analysis provides the strongest pooled evidence to date for tirzepatide's effectiveness in obesity management. The finding that over half of patients on the highest dose lose more than 15% of their body weight — approaching surgical levels of weight loss — positions tirzepatide as a potentially transformative non-surgical obesity treatment.
How the study worked
Systematic review and meta-analysis following PRISMA guidelines. Researchers searched PubMed, Cochrane Library, and EMBASE through December 2024 for randomized controlled trials comparing tirzepatide to placebo in adults with obesity, with or without type 2 diabetes. Ten RCTs met inclusion criteria. Pooled analyses calculated mean differences for weight and cardiometabolic outcomes.
What this study cannot tell us
The meta-analysis included trials with varying durations and populations (with and without type 2 diabetes), which introduces heterogeneity. Long-term safety and efficacy beyond the trial periods are not established. Publication bias cannot be fully excluded. The analysis compared tirzepatide to placebo only, not to active comparators like semaglutide. Weight regain after discontinuation was not assessed.
How to read the evidence
This is a systematic review and meta-analysis of 10 randomized controlled trials — the highest level of clinical evidence. The large pooled sample size (6,257 participants), consistent results across trials, and PRISMA-compliant methodology provide robust evidence for tirzepatide's efficacy and safety.
When this study was published
Published in 2025 with a literature search through December 2024, this meta-analysis captures the most comprehensive set of tirzepatide RCT data available.
The bigger picture
Tirzepatide's dual GIP/GLP-1 mechanism appears to produce greater weight loss than GLP-1-only drugs like semaglutide, establishing a new benchmark for pharmacological obesity treatment. This meta-analysis solidifies the evidence base as tirzepatide moves from clinical trials to widespread clinical use, and as newer triple-agonist compounds enter the pipeline.
Questions still open
- How does tirzepatide compare directly to semaglutide for weight loss in a meta-analytic framework?
- What are the long-term safety and weight maintenance outcomes beyond 2 years of tirzepatide use?
- Which patient subgroups derive the greatest cardiometabolic benefit from tirzepatide beyond weight loss alone?
Common questions
How much weight can you lose on tirzepatide?
Is tirzepatide safe for long-term use?
Read the original research
Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
Clinical obesity, 15(6), e70036
Citation
Wang, Jian-Ying; Kang, Jyun-Wei; Peng, Tzu-Rong; Chen, Hsin-Yen; Chen, Shih-Ming; Lee, Ming-Chia. (2025). Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.. Clinical obesity, 15(6), e70036. https://doi.org/10.1111/cob.70036